T cells engineered to express chimeric antigen receptors (CARs) that are specific for tumour
antigens have led to high complete response rates in patients with haematologic …

Highlights•CAR T cell clinical trial manufacturing data is investigated.•Three dominant
process routes are uncovered.•The trend in CAR T cell manufacturing is towards …

Promising efficacy results of chimeric antigen receptor (CAR) T-cell therapy have been
tempered by safety considerations. Our objective was to comprehensively summarize the …

Chimeric antigen receptor (CAR)–expressing T cells induce durable remissions in patients
with relapsed/refractory B cell malignancies. CARs are synthetic constructs that, when …

Currently, immunotherapy is attracting a lot of attention and may potentially become a
leading approach in the treatment of cancer. One emerging therapeutic, the chimeric …

Tumor lysis syndrome (TLS) is a potentially life-threatening emergency that can develop
rapidly after the release of intracellular contents from lysed malignant cells. The advent of …

Immunotherapy with T cells expressing chimeric antigen receptors (CAR) is an emerging
and promising treatment against refractory cancers. However, the currently adopted …

Background: Chimeric antigen receptor (CAR) T-cell therapy is a cellular immunotherapy
that redirects the killing activity of T cells to fight tumor cells. CD19 CAR T-cell therapies …

Les lymphocytes T ont un rôle important dans la réponse anti-cancéreuse. Ils reconnaissent
par leur TCR les antigènes tumoraux apprêtés sur le CMH des cellules présentatrices de …

Chimeric antigen receptor (CAR) T-cell therapy is an immunotherapy in which the patient's
own T cells are isolated in the laboratory, redirected with a synthetic receptor to recognize a …